
To demonstrate the efficacy of oral zzso 1 zzso twice daily for the prevention of late onset zzso and vomiting after moderately zzso chemotherapy that includes zzso zzso or zzso 

Prior to chemotherapy, patients were zzso by gender and zzso to receive oral zzso (1 zzso tablet twice zzso or zzso (10 zzso sustained release capsule twice zzso Study agents were administered 1 h prior to and 12 h after zzso zzso were administered for seven consecutive zzso zzso variables were assessed 48 and 72 h after administration of chemotherapy, and included no zzso no zzso no moderate or severe zzso and no zzso zzso Safety analysis included all patients who received zzso 

A total of 230 patients were included in the zzso zzso 119 patients received zzso and 111 patients received zzso zzso and all patients combined, who received zzso had significantly higher zzso rates at 48 h zzso zzso and p zzso zzso than patients who received zzso zzso rates at 48 h were zzso higher for all patients combined and females who received zzso rather than zzso Response rates for no zzso or mild zzso were also zzso higher in females treated with zzso compared to zzso at 48 zzso zzso more patients zzso zzso and females zzso zzso in the zzso group than in the zzso group did not require rescue zzso at 48 zzso At 72 zzso efficacy results were comparable for zzso and zzso 

zzso zzso is well tolerated and more effective than zzso in preventing zzso and vomiting for up to 48 h following treatment with moderately zzso zzso 

